

REMARKS

The specification has been amended to include a cross reference to the parent PCT application.

The specification has been amended to include the attached formal drawings. Acceptance of the formal drawings in the Examiner's next Action is requested.

The applicants elect, with traverse, the subject matter of the Examiner's Group III (claims 22 to 28) drawn to a method of treating a disease caused by the tumorigenic change of a hematopoietic cell comprising administering to a patient an anti-human VEGF receptor Flt-1, for further prosecution in the above. Moreover, the applicants elect, as single disclosed species, for purposes of initial examination, the VEGF receptor Flt-1 antibody KM-1732, and, as a fusion partner, a protein. All of the elected claims are submitted to read on the elected species.

The applicants note the Examiner's comments that upon the allowance of a generic claim, the applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. 1.141.

Reconsideration and withdrawal of the restriction requirement and election of species requirement are requested as a search of all the claimed subject matter is not believed to present an undue burden on the Examiner.


SHITARA et al
Appl. No. 09/914,837
October 31, 2003

Return of initialed copies of the PTO-1449 forms filed March 8, 2002 and October 25, 2001 and September 1, 2004 are requested pursuant to M.P.E.P. §609.

An early and favorable action on the merits of the claimed invention is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 
B. J. Sadoff
Reg. No. 36,663

BJS:pfc
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100